Equities

Oxford Biodynamics PLC

OBD:LSE

Oxford Biodynamics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)0.280
  • Today's Change-0.02 / -6.67%
  • Shares traded19.11m
  • 1 Year change-46.67%
  • Beta2.8634
Data delayed at least 20 minutes, as of Feb 06 2026 16:35 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Oxford BioDynamics Plc is a United Kingdom-based biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases. The Company is primarily engaged in the commercialization of proprietary molecular diagnostics products and biomarker research and development. Its products include EpiSwitch CiRT, EpiSwitch PSE, Specimen Submission Kit, and EpiSwitch Explorer. The EpiSwitch CiRT is a blood test which predicts an individual patient’s therapeutic response to checkpoint inhibitor immunotherapy. The EpiSwitch Explorer is a microarray kit for high-throughput, high-resolution 3D genome profiling. The Specimen Submission Kit is used for collecting samples from any location. The EpiSwitch platform offers reproducibly translating three-dimensional (3D) genome regulation for clinical applications. This platform provides a portfolio of clinical smart tests based on EpiSwitch technology.

  • Revenue in GBP (TTM)1.10m
  • Net income in GBP-11.15m
  • Incorporated2007
  • Employees44.00
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
BSF Enterprise PLC24.09k-1.60m2.57m4.002.57m4.00
Nuformix PLC0.00-652.59k4.85m3.004.85m3.00
CRISM' Therapeutics Corp25.00k-1.49m6.60m0.006.60m0.00
Oxford Biodynamics PLC1.10m-11.15m12.01m44.0012.01m44.00
Probiotix Health PLC2.22m-736.00k12.26m4.0012.26m4.00
CRUSHMETRIC Group Ltd-100.00bn-100.00bn20.62m17.0020.62m17.00
Data as of Feb 06 2026. Currency figures normalised to Oxford Biodynamics PLC's reporting currency: UK Pound GBX

Institutional shareholders

52.53%Per cent of shares held by top holders
HolderShares% Held
Vulpes Investment Management Pte Ltd.as of 11 Nov 2025618.54m14.42%
Pentwater Capital Management LPas of 11 Nov 2025500.00m11.65%
KW Investment Management Ltd.as of 01 Jan 2026416.13m9.70%
Unicorn Asset Management Ltd.as of 11 Nov 2025278.46m6.49%
Hargreaves Lansdown Fund Managers Ltd.as of 01 Jan 2026123.38m2.88%
James Brearley & Sons Ltd.as of 01 Jan 2026116.67m2.72%
Arbuthnot Latham & Co. Ltd.as of 01 Jan 202684.24m1.96%
IG Markets Ltd.as of 01 Jan 202643.16m1.01%
Cantor Fitzgerald Europeas of 04 Feb 202540.18m0.94%
Winterflood Securities Ltd (Market-Maker)as of 01 Jan 202633.08m0.77%
More ▼
Data from 31 Mar 2025 - 29 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.